← All trials
NCT04603989
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2020
- Primary completion
- Oct 18, 2020
- Completion date
- Oct 25, 2020
- First posted
- Oct 27, 2020
- Last posted
- Oct 27, 2020
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Guangzhou Henovcom Bioscience Co. Ltd.Lead sponsor
- Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.Collaborator
- Nanjing Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.